首页 | 本学科首页   官方微博 | 高级检索  
     


A review of cancer immunotherapy toxicity
Yuxuan Huang, Hongbiao Shen, Qi Tang. Research and progress of CAR-macrophage cell therapy for solid tumors[J]. Blood&Genomics, 2023, 7(2): 86-93. DOI: 10.46701/BG.2023022023020
Authors:Yuxuan Huang  Hongbiao Shen  Qi Tang
Affiliation:1.National Health Commission Key Lab. of Antibody Techniques, Nanjing Medical University, Nanjing, Jiangsu 211166, China;2.Department of Pathology, Nanjing Medical University, Nanjing, Jiangsu 211166, China
Abstract:Though chimeric antigen receptor T cell (CAR-T) technology has emerged as an effective breakthrough against hematological malignancies, its application to solid tumors remains challenging and is restricted by the high complicacy of the tumor microenvironment (TME). Macrophages are innate immune cells that are inherently equipped with a wide range of therapeutic effects, including elevated infiltration rate, enhanced phagocytosis and cytotoxicity, mediation of immune suppression, and antigen presentation. In light of these unique biological functions and their ability to penetrate tumors, macrophages have emerged as a promising approach for the treatment of solid tumors. This review initially clarifies the biological characteristics of macrophages and tumor-associated macrophages (TAMs), then reviews macrophage sources and the CAR design structure, outlines the ways to deliver CAR to macrophages and the preparation of CAR-macrophages (CAR-Ms), and finally summarizes the application and prospects for the treatment of solid tumors by CAR-Ms in recent years.
Keywords:chimeric antigen receptor  CAR-macrophage  tumor-associated macrophage  cell therapy  solid tumor
点击此处可从《Blood and Genomics》浏览原始摘要信息
点击此处可从《Blood and Genomics》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号